newsfilter
← Latest News
Earnings Call Transcripts·

Ovid Therapeutics - UBS Global Biopharma Conference - OVID THERAPEUTICS INC

  • Explicit Guidance:

    • Phase 2 Focal Epilepsy (OV329): Expected readout in the second half of 2027.
    • Photosensitivity Study (OV329): Open-label study readout expected in the first quarter of 2026 to de-risk pivotal dosing.
    • Pediatric Tuberous Sclerosis Complex (OV329): Open-label safety/signal-finding study initiation expected at the end of the current year.
    • Pediatric Infantile Spasms (OV329): Study initiation expected in 2027, contingent on the completion of the TSC study.
    • Phase 1 KCC2 Activator (OV4071): Study expected to conclude around Q1 2027.
    • Ketamine Challenge (OV4071): Study expected to conclude around the end of Q1 2026 to establish neuroactivity.
    • Phase 2 Acute Schizophrenia (OV4071): Intended start date around the middle of 2027.
  • Business-Segment Outlook:

    • OV329 (Epilepsy): Positioned as a differentiated mechanism targeting the enzyme that catabolizes GABA, aiming to replace a first-generation drug with historical safety baggage (retinal toxicity).
      • Adults: Developing a pill formulation for focal onset seizures in adults with broad potential therapeutic utility.
      • Pediatrics: Developing granule/sachet formulations for Tuberous Sclerosis Complex (TSC) and infantile spasms to address severe developmental epileptic encephalopathies.
      • Potential: Described as a "multi-billion dollar opportunity" with the potential to treat a broad array of seizure types, including those where current therapies fail.
    • OV4071 (KCC2 Portfolio): First-ever oral direct activator of the KCC2 target, intended to restore excitatory-inhibitory balance in the CNS.
      • Indication Strategy: Primary focus on acute schizophrenia for Phase 2 to leverage positive symptom endpoints as a proof of concept, though the mechanism has potential across psychosis, anxiety, pain, Rett syndrome, and other developmental epileptic encephalopathies.
      • Differentiation: Anticipated to improve positive, negative, and cognitive symptoms without the sedation typical of current antipsychotics, potentially serving as the "next PD-1 of the brain."
      • Pipeline Depth: Plans to utilize discovery engine to generate follow-on KCC2 candidates and backups.
  • Market and Competitive Outlook:

    • Epilepsy: Despite an increase in new drugs, the manager notes a persistent "unmet need" for a medication that is highly effective, safe, well-tolerated, and easy to use (once daily, no titration, no drug interactions) without tolerability baggage.
    • Psychiatry: Current market lacks a drug capable of simultaneously treating positive, negative, and cognitive symptoms of schizophrenia; KCC2 activation appears to address this triad.
    • Competitive Landscape: OV329 aims to differentiate from a historical first-generation drug (Lundbeck) that failed due to irreversible blindness and sedation. KCC2 targets are viewed as having been un-druggable for two decades, positioning Ovid as a pioneer in this specific modality.
  • Macro / Industry Outlook:

    • CNS Development: Management characterizes the broader CNS/neuropsychiatry landscape as previously suffering from a "sea of sameness" with incremental improvements, necessitating a shift toward fundamental targets (excitation/inhibition balance) for step-change patient benefits.
    • Target Validation: KCC2 is described as a master switch for neural hyperexcitability, with preclinical data across 40+ animal models and 100+ pharmacodynamic studies supporting broad therapeutic applicability.
  • Strategic Initiatives:

    • Pipeline De-risking: Execution of translational "killer experiments" and dedicated toxicology to prove OV329 does not accumulate in the eye (avoiding the retinal toxicity of the first-gen drug).
    • Biomarker Development: Utilization of Transcranial Magnetic Stimulation (TMS) to demonstrate cortical inhibition and a battery of EEG/ERP biomarkers to validate neuroactivity for OV4071 prior to pivotal trials.
    • Formulation Strategy: Differentiating adult and pediatric formulations (pill vs. sachet) to enable separate pricing and market entry strategies.
    • Capital Deployment: Management references a recent $175 million raise to fund the transition from Phase 1 to Phase 2 studies.
    • Timeline: Aggressive execution expected over the next 24 months to progress from Phase 1/2 initiation to pivotal data readouts.
  • Risks and Headwinds to Outlook:

    • Clinical Failure: Acknowledged risk that early signals in animal models may not translate to human efficacy, particularly in psychiatric indications which are noted as less trusted proxies than seizure models.
    • Safety Concerns: Specific historical risk regarding retinal toxicity associated with the GABA catabolism mechanism; Ovid relies on the hypothesis that their specific compound structure avoids this issue, but clinical failure would invalidate this.
    • Timeline Delays: Reliance on specific readouts (photosensitivity, Phase 1 completion) to gate subsequent studies; delays in these inflection points could push pivotal trials beyond current estimates.
    • Competitive Dynamics: The epilepsy market is described as "busy," implying potential competition from other new therapies.
  • Management Tone on the Future:

    • Confidence: Highly confident and enthusiastic; uses metaphors of being in the "playoffs and headed to the Super Bowl."
    • Conviction: Expresses strong belief in the "holy grail" potential of OV329 and describes the KCC2 opportunity as "unignorable" and potentially transformative.
    • Hedges: Management explicitly notes a conservative approach to psychiatric data, stating they "don't trust psych models the same way" as other disease models and rely heavily on animal/biomarker validation before human trials.
    • Pacing: Emphasizes a strategy of asking "hard questions early" to maximize learning and de-risk the path to commercialization.
  • Miscellaneous:

    • Financial Context: No explicit revenue or earnings guidance provided in this transcript; discussion focuses entirely on clinical milestones and the potential commercial value of the assets.
    • Company Status: Described as a publicly traded company with a "fully integrated pipeline" and a discovery engine supporting KCC2 expansion.
Company
OVID THERAPEUTICS INC
Keywords
OVID THERAPEUTICS INC